1. Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma;Ghobrial;Blood (ASH Annual Meeting Abstracts),2016
2. Trends in pre- and post-transplant therapies prior to first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004-2014;D'Souza;Blood (ASH Annual Meeting Abstracts),2016
3. Impact of treatment intensification according to patient prognosis: a pooled analysis of 3 randomized phase III trials;Gay;Blood (ASH Annual Meeting Abstracts),2016
4. RVD + ASCT + lenalidomide maintenance benefits patients without high-risk cytogenetics and results in recovery of the normal plasma cell composition in bone marrow;Silvennoinen;Blood (ASH Annual Meeting Abstracts),2016
5. Intensification therapy with bortezomib-melphalan-prednisone versus autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial);Cavo;Blood (ASH Annual Meeting Abstracts),2016